Authors: Xiaorui Xiong, PhD, et al.
Abstract: Digital therapeutics can expand the reach and fidelity of behavioral treatment for substance use disorders (SUDs). This analysis evaluated real-world engagement and clinical outcomes in patients diagnosed with SUDs who were prescribed reSET®, an FDA-authorized prescription digital therapeutic (PDT).
Patients with SUDs exhibited robust engagement with a PDT, high rates of retention through 12 weeks, and substantial rates of abstinence at the end of treatment when the therapeutic was used in a real-world setting. PDTs hold promise as a new way to access effective SUDs treatment, say the authors.
Importance: Substance use disorder (SUD), which includes dependence on alcohol, cannabis, stimulants, sedatives, or opioids, affects up to 41 million people in the US, and yet recent data shows that only about 6.5% of these people ever receive SUDs treatment.
This study is the first to report real-world PDT engagement and clinical outcomes data from a large, geographically diverse population of patients with SUDs.
Patient attrition from SUD treatment is a common barrier to successful recovery, thus treatments or programs that increase engagement with, and retention in, treatment may support recovery from SUDs. This evaluation strongly suggests that adults of all ages who fill a prescription for a PDT to treat SUDs readily engage with the PDT, many at the recommended content dose.
Availability: Published by The American Journal on Addictions